✦ LIBER ✦

H35 Baseline characteristics of the life (Losartan intervention for endpoint reduction) in hypertension study

✍ Scribed by B. Dahlöf; R. Devereux; U. DeFaire; F. Fyhrquist; T. Hedner; H. Ibsen; S. Julius; S. Kjeldsen; K. Kristianson; O. Lederballe-Pedersen; L. Lindholm; M. Nieminen; P. Omvik; S. Oparil; H. Wedel

Book ID: 117603252
Publisher: Nature Publishing Group
Year: 1997
Tongue: English
Weight: 285 KB
Volume: 10
Category: Article
ISSN: 0895-7061
DOI: 10.1016/s0895-7061(97)88956-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Losartan intervention for endpoint reduc

Losartan intervention for endpoint reduction in hypertension (the life study)

✍ DAHLOF, B 📂 Article 📅 1996 🏛 Nature Publishing Group 🌐 English ⚖ 193 KB

LIFE (losartan intervention for endpoint

LIFE (losartan intervention for endpoint reduction in hypertension) study and its substudies

✍ Claudio Borghi; Sibel Ertek 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 185 KB

Regression of hypertensive left ventricu

Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol. The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Trial

✍ R.B. Devereux; B. Dahlof; E. Gerdts 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 31 KB

Population impact of losartan use on str

Population impact of losartan use on stroke in the European Union (EU): Projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study

✍ Dahlöf, B; Burke, T A; Krobot, K; Carides, G W; Edelman, J M; Devereux, R B; Die 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 148 KB

The Effect of Losartan Versus Atenolol o

The Effect of Losartan Versus Atenolol on Cardiovascular Morbidity and Mortality in Patients With Hypertension Taking Aspirin: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study

✍ Eigil Fossum; Andreas Moan; Sverre E. Kjeldsen; Richard B. Devereux; Stevo Juliu 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 177 KB

Cardiovascular morbidity and mortality i

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

✍ Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beever 📂 Article 📅 2002 🏛 The Lancet 🌐 English ⚖ 124 KB